Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”
To the Editor:
Conflicts of Interest
References
- Neiser, S.; Koskenkorva, T.S.; Schwarz, K.; Wilhelm, M.; Burckhardt, S. Assessment of dextran antigenicity of intravenous iron preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185. [Google Scholar] [CrossRef] [PubMed]
- Ring, J.; Valenta, R. Letter to the Editor on the article “Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay”. Port. J. Nephrol. Hypertens. 2012, 26, 308–310. [Google Scholar]
- Neiser, S.; Wilhelm, M.; Schwarz, K.; Funk, F.; Geisser, P.; Burckhardt, S. Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay. Port. J. Nephrol. Hypertens. 2011, 25, 219–224. [Google Scholar]
- Auerbach, M.; Macdougall, I.C. Safety of intravenous iron formulations: Facts and folklore. Blood Transfus. 2014, 12, 296–300. [Google Scholar] [PubMed]
- Rodgers, G.M.; Auerbach, M.; Cella, D.; Chertow, G.M.; Coyne, D.W.; Glaspy, J.A.; Henry, D.H. High-molecular weight iron dextran: A wolf in sheep’s clothing? J. Am. Soc. Nephrol. 2008, 19, 833–834. [Google Scholar] [CrossRef] [PubMed]
- Kalra, P.A.; Bhandari, S. Safety of intravenous iron use in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2016, 25, 529–535. [Google Scholar] [CrossRef] [PubMed]
- Kreimeier, U.; Christ, F.; Kraft, D.; Lauterjung, L.; Niklas, M.; Peter, K.; Messmer, K. Anaphylaxis due to hydroxyethyl-starch-reactive antibodies. Lancet 1995, 346, 49–50. [Google Scholar] [CrossRef]
- Neiser, S.; Schwarz, K.; Wilhelm, M.; Funk, F.; Geisser, P.; Burckhardt, S. Reply to the letter to the editor by Johannes Ring and Rudi Valenta on the article “Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay”. Port. J. Nephrol. Hypertens. 2012, 26, 311–312. [Google Scholar]
- Grant, C.J.; Scott, R.A.; Mortimore, G.; Austin, A.S. Evaluation of the efficacy and safety of single dose iron infusion in clinical practice. Gut 2013, 62, A1–A50. [Google Scholar] [CrossRef]
- Wang, C.; Graham, D.J.; Kane, R.C.; Xie, D.; Wernecke, M.; Levenson, M.; MaCurdy, T.E.; Houstoun, M.; Ryan, Q.; Wong, S.; et al. Comparative risk of anaphylactic reactions associated With intravenous iron products. JAMA 2015, 314, 2062–2068. [Google Scholar] [CrossRef] [PubMed]
- Bager, P.; Hvas, C.L.; Dahlerup, J.F. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br. J. Clin. Pharmacol. 2016, 17. [Google Scholar] [CrossRef] [PubMed]
- Bijwerkingen Centrum Lareb 2015. Available online: http://www.lareb.nl/Signalen/Signals_2015_Intravenous_iron (accessed on 2 November 2015).
- Crichton, R.R.; Danielson, B.G.; Geisser, P. Iron Therapy with Special Emphasis on Intravenous Administration, 4th ed.; UNI-MED: Bremen, Germany, 2008. [Google Scholar]
- Kalra, P.A. Introducing iron isomaltoside 1000 (Monofer®)—Development rationale and clinical experience. NDT Plus 2011, 4, i10–i13. [Google Scholar] [CrossRef] [PubMed]
- Jahn, M.R.; Andreasen, H.B.; Fütterer, S.; Nawroth, T.; Schünemann, V.; Kolb, U.; Hofmeister, W.; Muñoz, M.; Bock, K.; Meldal, M.; et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 2011, 78, 480–491. [Google Scholar] [CrossRef] [PubMed]
© 2017 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Burckhardt, S. Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”. Int. J. Mol. Sci. 2017, 18, 122. https://doi.org/10.3390/ijms18010122
Burckhardt S. Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”. International Journal of Molecular Sciences. 2017; 18(1):122. https://doi.org/10.3390/ijms18010122
Chicago/Turabian StyleBurckhardt, Susanna. 2017. "Reply to “Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185.”" International Journal of Molecular Sciences 18, no. 1: 122. https://doi.org/10.3390/ijms18010122